abstract |
The present invention binds to the FLJ25416 transcript (mRNA) nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 7 to the expression of siRNA (small interfering RNA), FLJ25416 that inhibits the expression of FLJ25416 in cells It provides a pharmaceutical composition for treating cancer comprising at least one selected from antisense RNA (suppressive RNA), and deoxyribonucleic acid (DNA) encoding short hairpin RNA (shRNA) that inhibits the expression of FLJ25416. The siRNA, antisense RNA, and shRNA complementary to the nucleotide sequence of the FLJ25416 transcript of the present invention inhibit the expression of FLJ25416, which is known to be expressed on cancer cells, thereby killing cancer cells. Thus, the composition of the present invention can be used as a novel anticancer agent. Can be. |